PBAC's latest decision on Alogliptin: Recommended with restriction (2013). Considered for Type 2 diabetes mellitus in combination with metformin or a sulfonylurea in patients whose HbA1c is greater than 7% despite treatment with either metformin or a sulfonylurea and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2013
Submissions
1
2013 → 2013
Eligible population
Adults with type 2 diabetes in combination with metformin or a sulfonylurea, whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor, a thiazolidinedione or a glucagon-like peptide-1.
Therapy area
Endocrinology
Line of therapy
Later-line
Evidence base
RCT
Primary endpoint
HbA1c reduction
Pivotal trial size
1,609 patients
Key trials
MET-008, CCT-006, 308, SULF-007, CCT-005, Charbonnel et al. 2006, Scott et al. 2008, Raz et al. 2008, Hermansen et al. 2007
Comparator
sitagliptin
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis performed; no ICER calculated as the analysis was based on non-inferiority claim with equivalent effectiveness to sitagliptin.